ArticleOncoTargets and therapy2019
Downregulation Of microRNA-133b And Its Clinical Value In Non-Small Cell Lung Cancer.
Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 8 citations in OpenAlex.
- Long non‑coding RNA HCG18 facilitates the progression of laryngeal and hypopharyngeal squamous cell carcinoma by upregulating FGFR1 via miR‑133b.Molecular medicine reports · 2022Article
- Poorly Differentiated Neuroendocrine Larynx Carcinoma: Clinical Features and miRNAs Signature-A New Goal for Early Diagnosis and Therapy?Journal of clinical medicine · 2021Article
- MiR-1231 decrease the risk of cancer-related mortality in patients combined with non-small cell lung cancer and diabetes mellitus.Cancer cell international · 2020Article
- MicroRNA-374b-5p Functions as a Tumor Suppressor in Non-Small Cell Lung Cancer by Targeting FOXP1 and Predicts Prognosis of Cancer Patients.OncoTargets and therapy · 2020Article
- Upregulation of microRNA-1303 is a potential prognostic marker of non-small cell lung cancer.Cancer biomarkers : section A of Disease markers · 2020Observational
- miR-1323 Promotes Cell Migration in Lung Adenocarcinoma by Targeting Cbl-b and Is an Early Prognostic Biomarker.Frontiers in oncology · 2020Article
- MicroRNA-133b Inhibits nTumor Cell Proliferation, Migration and Invasion by Targeting SUMO1 in Endometrial Carcinoma.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have investigated the expression of miR-133b in non-small cell lung cancer (NSCLC); however, its underlying mechanism in relation to the pathogenesis of NSCLC remains unclear.
methodsThe aim of this study was to investigate the correlation between miR-133b expression and clinical parameters based on the Cancer Genome Atlas (TCGA) and real-time quantitative real-time PCR (RT-qPCR) data. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed to identify the biological function of miR-133b. A protein-protein interaction (PPI) network was constructed to screen for hub genes. The Gene Expression Profiling Interaction Analysis (GEPIA) and the Human Protein Atlas databases (HPAD) were employed to validate the hub genes. The cBioPortal database was used to identify neighboring genes with alteration frequencies greater than 20% gene alterations.
resultsmiR-133b was downregulated in NSCLC tissues, and expression was correlated with lymph node metastasis (P < 0.05). A total of 362 genes were considered as the potential targets of miR-133b in NSCLC. These candidate target genes highly enriched in various key pathways such as the PI3K-Akt pathways, P53 signal pathways, and ECM-receptor interaction. PPI revealed 10 genes as hub genes with node degrees ≥10.
conclusionThe study validated that miR-133b is downregulated in NSCLC. In addition, miR-133b might function as a biomarker for the diagnosis and prognosis of NSCLC. Bioinformatics analysis revealed that miR-133b could be involved in NSCLC metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.